Drug Development

RyboDyn's RyboCypher platform is uncovering a 'dark proteome' full of tumor-specific targets, promising a new era beyond today's crowded drug pipeline.

Amid a selective biotech market, Rakovina Therapeutics' oversubscribed placement highlights investor belief in its AI-powered strategy for next-gen cancer drugs.

A biotech's new funding offers a glimmer of hope for a novel cancer therapy, but a look at the books reveals a desperate race against time and capital.

Aardvark Therapeutics faces a pivotal moment as an FDA clinical hold halts its lead drug trial, leaving the Prader-Willi Syndrome community waiting.

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.

With pivotal data imminent for two cancer drugs and a fortified balance sheet, SELLAS is at a crucial inflection point. Can it deliver on its promise?

Kodiak Sciences launches a pivotal trial for a new drug aiming to best current treatments for diabetic eye disease. Is this the future of vision care?

As VolitionRx readies its Q2 update, investors and scientists look for proof that its pioneering epigenetic tests can translate into commercial success.

A novel dual-action antibody shows remarkable durability in Phase 2 trials, offering a potential six-month dosing schedule for millions with chronic sinusitis.

With a strong cash position and key clinical trials advancing for ALS and FTD, Coya is executing a disciplined strategy to tackle neurodegenerative diseases.

A new partnership between Carelon Research and Manifold promises to unlock life sciences insights by letting researchers analyze sensitive health data without moving it.

The biotech has gone all-in on its lead drug, bel-sar, cutting 20% of staff and shelving a promising bladder cancer program to secure its financial future.

With promising data for its lead cancer drug and a fortified financial runway, C4 Therapeutics is executing a tangible plan to fight a relentless disease.

With 92% response rates in a deadly cancer and $1B in the bank, Tango Therapeutics is not just developing a drug—it's building a new industrial model for precision oncology.

With a massive Series B and the launch of a Phase 3 study, Vaderis Therapeutics is poised to deliver the first-ever approved therapy for a long-neglected rare disease.

As Johnson & Johnson prepares for a key investor conference, its strategy hinges on a potent mix of new drugs, robotic surgery, and a leaner focus.

With a strong cash runway, Nkarta pushes its off-the-shelf NK cell therapy into community clinics, setting the stage for a pivotal data reveal in 2026.

With promising early data and a robust balance sheet, Palisade Bio is advancing its targeted IBD therapy, PALI-2108, into crucial Phase 2 trials.

With major clinical trials progressing and a $110M war chest, Orchestra BioMed is orchestrating a potential shift in cardiovascular treatment.

Metagenomi Therapeutics is on track for a pivotal 2027 clinical trial, but its advanced gene editing tech faces a market wary of high-cost cures.